Key points from article :
Neuralink has announced a new trial that could transform the lives of patients with paralysis due to spinal cord injury (SCI) or neurodegenerative diseases like ALS. The trial, named CONVOY, aims to test the N1 brain-computer interface (BCI) implant's ability to control a robotic arm, offering a significant advancement over its current functionality, which allows patients to control a computer cursor with their thoughts. If successful, this could help restore both physical and digital freedom for people with severe mobility impairments.
The N1 implant uses tiny threads with electrodes that detect neural signals in the brain, allowing patients to control devices like robotic arms. These threads are so delicate that they must be implanted using a robotic surgeon. Neuralink's latest developments also include the international CAN-PRIME study in Canada, which will assess the implant's safety and its effects on cognition in patients with severe tetraplegia.
In addition to the CONVOY and CAN-PRIME studies, Neuralink has been granted FDA breakthrough status for its Blindsight BCI, designed to help people with vision impairment regain sight, even without functioning eyes or optic nerves. This series of advancements highlights the growing potential of BCIs in improving quality of life for people with disabilities.
